Presentations and Publications

Reneo Pharmaceuticals Research

PPARδ Agonist Mavodelpar (REN001) Improves Mitochondrial Function in Skeletal Muscle: an Investigational Treatment for Primary Mitochondrial Myopathies*

Adams et al., UMDF 2023

Click to view

Clinical Manifestations and Disease Burden of Primary Mitochondrial Myopathies (PMM): Results from a Patient Journey Analysis Shows Substantial Healthcare Resource Utilization

Sirimanne et al., UMDF 2023

Click to view

From Clinical Manifestations of Primary Mitochondrial Myopathies (PMM) to Diagnosis: Results from a Patient Journey Analysis Shows Limited Utilization of Genetic Testing

Sirimanne et al., UMDF 2023

Click to view

Mavodelpar clinical development program in adult patients with primary mitochondrial myopathies (PMM): Design of the ongoing pivotal study (STRIDE) based on results from Phase 1b PMM study in adult patients

Pitceathly et al., UMDF 2023

Click to view

Mavodelpar clinical development program in adult patients with primary mitochondrial myopathies (PMM): Design of the ongoing pivotal study (STRIDE) based on results from Phase 1b PMM study in adult patients

Pitceathly et al., Euromit 2023

Click to view